Table 2.
Drug-Loading Method | Polymeric Support | Active Principle | Application | Outcome | Ref. |
---|---|---|---|---|---|
Soaking method | Polyurethane film produced by solvent casting | Brimonidine tartrate |
Glaucoma | Prolonged drug release up to 14 days | [38] |
Drug-loaded liposomes by hydration method; soaking method |
Lipids-based film | Besifloxacin hydrochloride | Conjunctivitis | Biphasic release: initial burst + sustained (80% released in 10 h) | [39] |
- | DMA film placed on commercial CLs loaded with AIBN | Loading of vitamin E | - | AIBN release in about 30 min | [40] |
Solvent casting | PLGA film embedded in methafilcon hydrogel- based CLs | Dexamethasone | Retinal diseases, such as diabetic macular edema | Prolonged drug release up to 160 h | [30] |
Solvent casting | PLGA film embedded in HEMA hydrogel-based CLs | Ciprofloxacin | Post-operative treatment | Prolonged drug release for 1 month | [27] |
Solvent casting | PLGA film embedded in HEMA hydrogel-based CLs | Econazole | Fungal keratitis |
Extended antifungal activity | [29] |
Solvent casting | PLGA film embedded in methafilcon hydrogel- based CLs | Latanoprost | Glaucoma | Initial burst + sustained drug release for 1 month. | [31] |
Solvent casting | PLGA film embedded in methafilcon hydrogel- based CLs | Latanoprost | Ocular hypertension, glaucoma |
Sustained drug delivery as effective as eyedrops | [32] |
Solvent casting | Hydrogel-based CLs | Voriconazole loaded into GO; HTCC and silver nanoparticles as antimicrobial agents |
Fungal Keratitis |
Good antifungal and antimicrobial activity | [43] |
Soaking or mixing method |
PVA/collagen membrane |
Ciprofloxacin hydrochloride, tobramycin |
Ulcerative keratitis |
Antibacterial activity for 48 h | [42] |
Soaking method | HEMA hydrogels with/without APMA |
rAAV | Corneal gene therapy | Efficacy in transduction/ triggering cell proliferation | [44] |
Soaking method | Silicone hydrogels | Levofloxacin, chlorhexidine, diclofenac, timolol | - | High burst in the release profiles, optimization of sterilization method | [33] |
Soaking method | Hydrogels based on HEMA, silicone, NVP and MMA | HPMC | - | pH-sensitivite drug release | [28] |
Soaking method | PEG-modified silicone hydrogel | Roscovitine | Retinoblastoma | Prolonged drug release | [34] |
Soaking method | HEMA/β-CD- hyaluronan hydrogels | Diclofenac sodium | Conjunctivitis | Therapeutic effect for conjunctivitis | [45] |
Soaking method | Commercial hydrogel- based CLs | Voriconazole, diclofenac sodium | Acanthamoeba keratitis | Sustained release, cell proliferation | [46] |
Soaking method | HEMA hydrogel- based CLs | Triamcinolone acetonide | Allergy | Prolonged drug release | [47] |
Soaking method | Commercial HEMA hydrogel- based CLs | Timolol maleate | - | High-burst: 95% of drug released in 2 h | [48] |
Soaking method from a solution or microemulsion |
CLs based on siloxane, DMA, EGDMA, HEMA, Irgacure | Bimatoprost | Glaucoma | Microemulsion better than solution to prolong release | [20] |
Soaking method | Commercial CLs based on silicone or HEMA hydrogels | Tetracaine, bupivacaine, ketotifen, diclofenac, flurbiprofen; loading of fatty acids (i.e., oleic acid, linoleic, α-linolenic acid) | - | Prolonged drug release, with an initial burst in the range 30–90% depending on the drug/CLs system | [49] |
Soaking method | Commercial silicone hydrogel CLs | Timolol maleate; loading of vitamin E |
Ocular hypertension, glaucoma |
High drug bioavailability, reduction of hypertension | [35] |
Soaking method | HEMA-based hydrogels with EGDMA, GMA, NVP, AIBN | Alexa Fluor 488 dye, brimonidine, timolol; loading of vitamin E and A | Glaucoma | Increase in drug loading, drug release in 6 h | [50] |
Soaking method | Commercial silicone hydrogel CLs | Fluconazole, dexamethasone, timolol maleate; vitamin E loading |
Eye inflammation, glaucoma | Prolonged drug release, beneficial effect of blocking UV radiation | [36] |
Soaking method | Commercial CLs based on senofilcon A | Timolol maleate, dorzolamide hydrochloride; vitamin E loading | Glaucoma | Prolonged drug release | [51] |
Soaking method | Commercial silicone hydrogel CLs | Dexamethasone; vitamin E loading | Eye inflammation |
Prolonged drug release | [52] |
Drug/BSA NCs by acid-base neutralization reactions; soaking method | NCs based on BSA and loaded into HEMA hydrogels | Meloxicam | Ocular irritation, antophthalmia after cataract surgery | Reduction of eye irritation, extended drug release | [53] |
Drug-loaded micelles by thin-film hydration method | PEG-b-PCL micelles (with a PCL core and silica shell) loaded into HEMA hydrogels | Dexamethasone | Chronic posterior segment eye diseases | Prolonged drug release up to 30 days | [54] |
- | PEG-b-PCL micelles into HEMA hydrogels | DDAO dye | - | Extended release for at least 14 days | [23] |
Drug-loaded liposomes placed on CLs by multilayer immobilization; soaking method |
Commercial CLs | Levofloxacin | Bacterial infections, such as keratitis | Antibacterial activity against Staphylococcus aureus | [55] |
Drug-laden liposomes loaded into hydrogels by free radical solution polymerization | DMPC liposomes loaded into HEMA-hydrogel CLs | Lidocaine | - | Drug release prolonged for about 7 days | [56] |
Drug-loaded lipid NPs by melt-emulsification and ultrasonication method; soaking | Compritol 888 ATO and triglyceride as lipid carriers for NPs soaked into hydrogels based on CMC and poloxamer 407 | Quercetin | - | Improvement in drug transcorneal penetration and the precorneal retention time |
[37] |
Drug/PGT NPs by thermal polymerization; soaking method | PGT-based NPs loaded into commercial silicone hydrogel CLs | Timolol maleate | Ocular hypertension, glaucoma | Prolonged drug release, reduction in hypertension, optimization of storage conditions | [57] |
Drug/silica NPs by microemulsion | Drug/silica shell NPs loaded into HEMA-based hydrogels | Lidocaine | Glaucoma | Prolonged drug release kinetics, with a 50% burst effect | [4] |
Drug/Eudragit NPs by quasi-emulsion solvent diffusion; soaking for direct- drug-loaded CLs |
pH-sensitive drug/Eudragit S100 NPs laden into hydrogel CLs | Cyclosporine | Chronic dry eyes syndrome | Prolonged drug release up to 14 h, no leaching after packaging | [19] |
Drug/silica NPs by microemulsion; direct-drug-loaded CLs by free radical polymerization |
Drug/silica shell NPs loaded into hydrogels based on HEMA, MAA, EGDMA | Ketotifen fumarate | Allergy | Reduced loss in transmittance and physical properties of hydrogels with NPs by emultion | [21] |
Drug-loaded EC NPs by double emulsion | Drug/EC NPs into ring implants based on HEMA, EGDMA and MAA, then incorporated into hydrogel CLs | Timolol maleate | Glaucoma | Sustained drug release and reduction in intraocular pressure (for 170 h /190 h) |
[25] |
Soaking method | CLs based on HEMA, DMA, EGDMA, NVP, siloxane and Irgacure |
Timolol maleate, gold NPs |
- | Rapid drug release in a few hours, reduction in intraocular pressure | [58] |
Soaking method | Drug-loaded semi-circular rings based on HEMA, MAA, EGDMA and Irgacure D, then implanted into hydrogel CLs | Moxifloxacin HCl, hyaluronic acid | Conjunctivitis | Improvement in drug residence time, bactericidal activity, optimization of sterilization method | [26] |
Cast moulding | Drug- loaded semi-circular acrylate rings implanted in CLs | Timolol maleate, hyaluronic acid | Glaucoma | High burst in drug release, optimization of sterilization | [59] |
Solvent casting for drug-loaded implants; soaking method for direct-drug-loaded CLs |
Silicone CLs; implants based on Irgacure, EGDMA, DMA, NVP, siloxane, HEMA, then embedded into silicone CLs |
Bimatoprost, hyaluronic acid, timolol |
Ocular hypertension, glaucoma |
High burst effect in drug release profiles | [24] |
Molecular imprinting |
Hydrogels based on HEMA, DEAA, DMA, SiMA, MMA | Timolol maleate | Glaucoma | Fast release, increase in drug loading by imprinting | [22] |
Molecular imprinting |
Hydrogels based on HEMA, EGDMA, MAA, AIBN | Acyclovir, valacyclovir hydrochloride |
Herpes simplex virus ocular keratitis | High drug loadings | [60] |
Soaking method; supercritical impregnation | Commercial hydrogel CLs based on Methafilcon A, Nelfilcon A, Omafilcon A, Hilafilcon B | Flurbiprofene, timolol maleate | Glaucoma | Higher drug loadings with shorter process times by sup. impregnation | [61] |
Soaking method; supercritical impregnation | Foldable acrylic hydrogel CLs, based on HEMA and BEM with MAA and acrylamide | Norfloxacin | Cataract | Higher drug loadings by supercritical impregnation | [62] |
Supercritical impregnation | Commercial silicone CLs based on Hilafilcon B | Salicylic acid | - | Prolonged drug release for 8 h | [63] |
Supercritical impregnation | Commercial rigid CLs based on PMMA | Cefuroxime sodium | Cataract | Prolonged drug release for 15 days | [64] |
Supercritical impregnation | Commercial silicone hydrogel CLs, based on Balafilcon A | Acetazolamide, timolol maleate | Glaucoma | Higher drug loadings | [65] |
Supercritical impregnation | Foldable acrylic CLs, based on HEMA | Dexamethasone, ciprofloxacin | Cataract | Prolonged drug release for 60 days | [66] |
Supercritical impregnation | Commercial foldable acrylic CLs | Gatifloxacin | Endophthalmitis after cataract surgery | Imrpovement in impregnation yield | [67] |
Supercritical impregnation | P(MMA-EHA-EGDMA) films | Flurbiprofen | Eye surgery | Prolonged drug released in 3 months | [68] |
Supercritical impregnation | Commercial foldable acrylic CLs | Methotrexate | Posterior capsule opacification after cataract surgery | Prolonged drug release for more than 100 days, inhibition of fibrosis | [69] |
Supercritical impregnation | Commercial silicone CLs, based on Balafilcon A | Acetazolamide | Glaucoma | Fast drug release in about 3 h | [70] |
Supercritical impregnation | Commercial rigid CLs based on PMMA | Dexamethasone, ciprofloxacin | Prevention of short- and mid-term postoperative complications | Prolonged drug release up to about 40 days | [71] |
Supercritical CO2- assisted molecular imprinting | Commercial silicone CLs | Flurbiprofen | - | Prolonged drug release up to about 8 h | [72] |